NIT
ACRS icon

NumerixS Investment Technologies’s Aclaris Therapeutics ACRS Stock Holding History

NumerixS Investment Technologies’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-9,200
Closed -$170K – 1090
2018
Q1 		$170K Buy
+9,200
New +$195K 0.04% 461
2017
Q4 		– Sell
-3,990
Closed -$103K – 1100
2017
Q3 		$103K Buy
+3,990
New +$107K 0.02% 745

Other funds holding ACRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

NumerixS Investment Technologies's ACRS Position: Q2 2018 in Review

NumerixS Investment Technologies sold out of Aclaris Therapeutics (ACRS) in Q2 2018, closing a stake of 9,200 shares — an estimated $170K sold.

NumerixS Investment Technologies first reported a position in ACRS in Q3 2017 and held it in 2 quarters. The position peaked at $170K in Q1 2018. 96 funds tracked by Wall St. Rank hold ACRS as of Q2 2018.

  • NumerixS Investment Technologies reported no remaining Aclaris Therapeutics position as of Q2 2018 after selling out during the quarter.
  • NumerixS Investment Technologies sold 9,200 Aclaris Therapeutics shares in Q2 2018, an estimated $170K.
  • NumerixS Investment Technologies first reported a position in Aclaris Therapeutics in Q3 2017 and held it in 2 quarters.
  • NumerixS Investment Technologies's Aclaris Therapeutics position peaked at $170K in Q1 2018.
  • 96 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2018.

Based on NumerixS Investment Technologies's 13F filing for Q2 2018, filed 10 Aug 2018.